As per Zion Market Research, the global antisense and RNAi therapeutics market is anticipated to register a growth at a CAGR of 8.3% during the forecasted period 2019–2025. Antisense technology presents the opportunity to control gene expression and this is believed to be an effective treatment for many diseases. Owing to this, companies are investing in research & development in this segment. The antisense and RNAi therapeutics permit precise and highly efficient gene silencing, due to this many gene silencing drugs are in the advanced stage of development. The global market is likely to grow over the forecasted period due several organizations that are into the advancement of molecules based on antisense technology.
Some of the key players in the market are Sanofi-Genzyme; GSK; Marina Biosciences; Alnylam Pharmaceuticals; Benitec Biopharma; Ionis Pharmaceuticals; Quark Pharmaceuticals; Akcea Therapeutics; and Gene Signal. These companies are focused on the advancement of RNAi therapies and platforms that provide diagnostics, medicines, and personalized treatment alternatives for key diseases.
Ribonucleic Acid Silencing Discovery Will Pave Ways For Treatments And Accelerate The Global Market
Besides partnerships between therapeutic developments and pharmaceutical firms, agreements are taking place amid outsourcing partners & operating entities. The latest trends, as per industry veterans, hold robust growth prospects for the overall market. Furthermore, the breakthrough of ribonucleic acid silencing has unlocked possibilities for treatments, which are advanced by using the interference mechanism of RNA. Nonetheless, the market is yet to develop at the desired rate, as complexities concerning delivering target molecules to aim organs continue to irk drug developers and scientists.
The global antisense and RNAi therapeutics market is bifurcated on the basis of technology, application, route of administration, and regional analysis. Based on technology, the market is divided into siRNA, RNA interference, miRNA, and antisense RNA. Based on the application, the market is divided into CVDs (cardiovascular diseases), oncology, renal diseases, respiratory disorders, genetic disorders, infectious diseases, neurodegenerative disorders, and others. Based on the route of administration, the market is divided into pulmonary delivery, intradermal injections, intravenous injections, topical delivery, intraperitoneal injections, and other delivery methods.
North America & Asia Pacific Region To Witness Massive Growth In The Global Antisense And RNAi Therapeutics Market
Based on geographical analysis, the global antisense and RNAi therapeutics market is divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America region showcased the most profitable prospects in the past and has, therefore, accounted for a significant share of the overall industry. The region boasts a mounting number of clinical trials and administration regulations therein support the course of initiation for advancing antisense therapeutics. In addition to this, a huge number of clinical laboratories are involved in research and development activities, which has affirmed major growth in the North America region in the upcoming years. Nevertheless, in the phase post commercialization of these treatments, the prospects across the Asia Pacific are anticipated to get more remunerative, exhibiting a higher development rate. The increasing administration spending in research and development in contemporary, besides other forms of siRNA delivery methods, is a robust factor helping the market’s trajectory in the Asia Pacific.
Get Sample of this Report for more Insights – https://www.zionmarketresearch.com/sample/antisense-and-rnai-therapeutics-industry
This review is based on a report by Zion Market Research, titled “Antisense And RNAi Therapeutics Market – Segmented By Technology (siRNA, RNA Interference, miRNA, Antisense RNA), Application (Cardiovascular Diseases, Oncology, Renal Diseases, Respiratory Disorders, Genetic Disorders, Infectious Diseases, Neurodegenerative Disorders, Others), Route Of Administration (Pulmonary Delivery, Intradermal Injections, Intravenous Injections, Topical Delivery, Intraperitoneal Injections, Other Delivery Methods), And Geography – Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2025”
The global antisense and RNAi therapeutics market is segmented as follows:
- RNA Interference
- Antisense RNA
- Respiratory Disorders
- Renal Diseases
- CVDs (Cardiovascular Diseases)
- Infectious Diseases
- Neurodegenerative Disorders
- Genetic Disorders
By route of administration:
- Intradermal Injections
- Intraperitoneal Injections
- Pulmonary Delivery
- Intravenous Injections
- Topical Delivery
- Other Delivery Methods
- North America
- The U.S.
- The U.K.
- Asia Pacific
- Latin America
- Middle East and Africa
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us – after all – if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651